Literature DB >> 23427875

Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia.

Tobias Svensson1, Martin Höglund, Honar Cherif.   

Abstract

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) and hypogammaglobulinemia who suffer from recurrent infections can be offered prophylactic intravenous immunoglobulin (Ig) substitution. Our aim was to assess the prevalence of pure IgG subclass deficiency (with normal Ig levels), its correlation to risk of infection, and the clinical value of routine measurement of serum IgG subclass levels in patients with CLL.
METHODS: Serum levels of Ig and IgG subclasses were determined in patients with CLL at Uppsala University Hospital. Clinical data were collected through patient records and questionnaires.
RESULTS: Hypogammaglobulinemia occurred in 52.3% out of 111 patients. These patients did not have a higher annual risk of infection than patients without hypogammaglobulinemia (79.5% vs 79.1%, p = 0.706 for all infections; 13.4% vs 11.2%, p = 0.394 for severe infection; and 1.7% vs 3.4%, p = 0.083 for sepsis). Pure subclass deficiency was uncommon and occurred in 6 patients (5.4%). The annual overall risk of infection, of severe infection, and of sepsis for these patients did not differ as compared to patients with no hypogammaglobulinemia and no subclass deficiency (70.8% vs 80.7%, p = 0.334; 11.8% vs 11.1%, p = 0.497; and 8.9% vs 2.3%, p = 0.067, respectively).
CONCLUSIONS: Pure IgG subclass deficiency is rare in patients with CLL. In this heterogeneous cohort of patients, neither hypogammaglobulinemia nor pure IgG subclass deficiency were significant risk factors for infectious complications. Measurement of serum levels of Ig may be justified in patients with recurrent severe infections, but routine analysis of IgG subclass levels in patients with CLL is probably not warranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23427875     DOI: 10.3109/00365548.2013.769279

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  6 in total

1.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Authors:  Sameer A Parikh; Jose F Leis; Kari G Chaffee; Timothy G Call; Curtis A Hanson; Wei Ding; Asher A Chanan-Khan; Deborah Bowen; Michael Conte; Susan Schwager; Susan L Slager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

2.  Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies.

Authors:  Laura García-Bravo; Myriam Calle-Rubio; Miguel Fernández-Arquero; Kauzar Mohamed Mohamed; Teresa Guerra-Galán; María Guzmán-Fulgencio; Antonia Rodríguez de la Peña; Cristina Cañizares; Bárbara López; Cristina Vadillo; Jorge Matías-Guiu; Asunción Nieto Barbero; José Luis Álvarez-Sala Walther; Silvia Sánchez-Ramón; Juliana Ochoa-Grullón
Journal:  J Transl Autoimmun       Date:  2022-06-30

3.  Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients.

Authors:  Namrata Singh; Sarah L Mott; Grerk Sutamtewagul; Ashley McCarthy; Susan L Slager; James R Cerhan; Zuhair Ballas; Brian K Link
Journal:  EJHaem       Date:  2020-09-01

Review 4.  Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.

Authors:  Silvia Sánchez-Ramón; Fatima Dhalla; Helen Chapel
Journal:  Front Immunol       Date:  2016-08-22       Impact factor: 7.561

5.  Secondary Immunodeficiency Frequency in Patients with Chronic Lymphocytic Leukemia: The Relationship with Stage and Treatment.

Authors:  Osman Yokus; Konul Jafarli; Fettah Sametoglu; Hasan Goze; Istemi Serin
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2022-01-01

6.  Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies.

Authors:  P Kralickova; J Kuhnova; O Soucek; P Vodarek; P Zak; M Simkovic; M Motyckova; L Smolej; E Mala; C Andrys; J Krejsek; V Thon
Journal:  J Immunol Res       Date:  2017-12-17       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.